Another Rac1 and Cdc42 dual-inhibitor, AZA1, identified from a screen of molecules based on modifying the structure of NSC23766, has been used in in vitro studies to target prostate cancer cells.125. This evidence concerns the gene RAC1 and Familial prostate cancer.